Last $22.81 USD
Change Today +0.64 / 2.89%
Volume 15.1K
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

ardelyx inc (ARDX) Snapshot

Open
$22.57
Previous Close
$22.17
Day High
$23.60
Day Low
$22.04
52 Week High
10/6/14 - $25.23
52 Week Low
08/7/14 - $11.37
Market Cap
422.9M
Average Volume 10 Days
20.4K
EPS TTM
--
Shares Outstanding
18.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARDELYX INC (ARDX)

Related News

No related news articles were found.

ardelyx inc (ARDX) Related Businessweek News

No Related Businessweek News Found

ardelyx inc (ARDX) Details

Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal and metabolic diseases. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was founded in 2007 and is headquartered in Fremont, California.

35 Employees
Last Reported Date: 11/7/14
Founded in 2007

ardelyx inc (ARDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $416.3K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $310.0K
Vice President of Drug Development
Total Annual Compensation: $277.5K
Compensation as of Fiscal Year 2013.

ardelyx inc (ARDX) Key Developments

Ardelyx, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Ardelyx, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total revenue was $7,598,000 compared to $6,593,000 a year ago. Income from operations was $81,000 compared to loss from operations of $886,000 a year ago. Income before provision for income taxes was $74,000 compared to loss before provision for income taxes of $899,000 a year ago. Net income and comprehensive income was $74,000 compared to net loss and comprehensive loss of $934,000 a year ago. The increase in net income was primarily driven by the increase in recognized licensing revenue related to milestone payments in accordance with the Company's agreement with AstraZeneca partially offset by expenses related to being a public company following the Company's June 2014 IPO and increased R&D expenses. Net income attributable to common stockholders - Diluted was $74,000 compared to loss attributable to common stockholders of $934,000 a year ago. For the nine months, the company's total revenue was $25,284,000 compared to $5,967,000 a year ago. Income from operations was $2,369,000 compared to loss from operations of $2,147,000 a year ago. Income before provision for income taxes was $757,000 compared to loss before provision for income taxes of $2,189,000 a year ago. Net income and comprehensive income was $757,000 compared to net loss and comprehensive loss of $2,295,000 a year ago.

Ardelyx, Inc. to Report Q3, 2014 Results on Nov 06, 2014

Ardelyx, Inc. announced that they will report Q3, 2014 results on Nov 06, 2014

Ardelyx, Inc., Q3 2014 Earnings Call, Nov 06, 2014

Ardelyx, Inc., Q3 2014 Earnings Call, Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARDX:US $22.81 USD +0.64

ARDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARDX.
View Industry Companies
 

Industry Analysis

ARDX

Industry Average

Valuation ARDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.4x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARDELYX INC, please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.